The dermatology diagnostic devices and therapeutics market would grow at a CAGR of 8.89% over the predicted time frame. The market is expected to increase in value from US$ 17.65 Bn in 2022 to US$ 8.89 Bn in 2030.
The on dermatology diagnostic devices and therapeutics Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2409
A recent report provides crucial insights along with application based and forecast information in the Global Dermatology diagnostic devices and therapeutics Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Dermatology diagnostic devices and therapeutics market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Dermatology diagnostic devices and therapeutics market are included as given below:
Dermatology diagnostic devices and therapeutics Market Key Players
- Canfield Scientific, Inc.
- Novartis International AG
- Valeant Pharmaceuticals International, Inc.
- gfa-Gevaert N.V.
- Galderma S.A.
- Michelson Diagnostics Ltd.
- Cutera, Inc.
- Astellas Pharma, Inc.
- Genentech
- GlaxoSmithKline plc
- LEO Pharma A/S
- Dino-Lite Europe/IDCP B.V.
Market Segments
By Diagnostic Devices
- Dermatoscopes
- Microscopes and Trichoscopes
- Imaging Equipment
By Application Class
- Diagnostic Devices
- Skin Cancer Diagnosis
- Other
- Treatment Devices
- Hair Removal
- Skin Rejuvenation
- Acne, Psoriasis, and Tattoo Removal
- Wrinkle Removal and Skin Resurfacing
- Body Contouring and Fat Removal
- Cellulite Reduction
- Vascular and Pigmented Lesion Removal
- Others
By End Use
- Hospitals
- Clinics
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, describe, and forecast the global dermatology diagnostic devices and therapeutics market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the dermatology diagnostic devices and therapeutics market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Dermatology Diagnostic Devices And Therapeutics Market
5.1. COVID-19 Landscape: Dermatology Diagnostic Devices And Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Dermatology Diagnostic Devices And Therapeutics Market, By Diagnostic Devices
8.1. Dermatology Diagnostic Devices And Therapeutics Market, by Diagnostic Devices, 2022-2030
8.1.1 Dermatoscopes
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Microscopes and Trichoscopes
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Imaging Equipment
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Dermatology Diagnostic Devices And Therapeutics Market, By Application Class
9.1. Dermatology Diagnostic Devices And Therapeutics Market, by Application Class, 2022-2030
9.1.1. Diagnostic Devices
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Treatment Devices
Chapter 10. Global Dermatology Diagnostic Devices And Therapeutics Market, By End Use
10.1. Dermatology Diagnostic Devices And Therapeutics Market, by End Use, 2022-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
Chapter 11. Global Dermatology Diagnostic Devices And Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.1.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.1.3. Market Revenue and Forecast, by End Use (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End Use (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End Use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.2.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.2.3. Market Revenue and Forecast, by End Use (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End Use (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End Use (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End Use (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End Use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.3.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.3.3. Market Revenue and Forecast, by End Use (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End Use (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End Use (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End Use (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End Use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.4.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.4.3. Market Revenue and Forecast, by End Use (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End Use (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End Use (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End Use (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End Use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.5.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.5.3. Market Revenue and Forecast, by End Use (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End Use (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Application Class (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End Use (2017-2030)
Chapter 12. Company Profiles
12.1. Canfield Scientific, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis International AG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Valeant Pharmaceuticals International, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. gfa-Gevaert N.V.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Galderma S.A.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Michelson Diagnostics Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Cutera, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Astellas Pharma, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Genentech
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. GlaxoSmithKline plc
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments